H.R. 1613 118th Congress
Drug Price Transparency in Medicaid Act of 2023
- Health
- Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1]
- Congress.gov ↗
Latest action, Mar 24, 2023: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
37 cosponsors
Sponsored by Rep. Carter, Earl L. "Buddy" [R-GA-1] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
14 D · 23 R
Referred to: House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
8 reports
8 reports
8 reports
8 reports
7 reports
7 reports
INDIANA UNIVERSITY HEALTH INC
DEBORAH HOHLT
7 reports
7 reports
7 reports
THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES)
BANNER PUBLIC AFFAIRS, LLC
7 reports
7 reports
The top 25 of 46 clients, by reports
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| FOOD MARKETPLACE INC | 8 | $2.7M | Q1 2023 | Q3 2024 | yes | |
| INDEPENDENT PHARMACY COOPERATIVE | 8 | $370K | Q1 2023 | Q3 2024 | yes | |
| KROGER CO | 8 | $3.1M | Q1 2023 | Q3 2024 | yes | |
| NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 8 | $5.5M | Q1 2023 | Q3 2024 | yes | |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 8 | $2.9M | Q1 2023 | Q3 2024 | yes | |
| TEVA PHARMACEUTICALS USA INC | 8 | $4.4M | Q1 2023 | Q3 2024 | yes | |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 7 | $20.1M | Q4 2023 | Q3 2024 | yes | |
| CVS HEALTH (AND SUBSIDIARIES) | 7 | $14.0M | Q4 2023 | Q3 2024 | yes | |
| INDIANA UNIVERSITY HEALTH INC | 7 | $790K | Q4 2023 | Q3 2024 | yes | |
| INDIANA UNIVERSITY HEALTH INC | DEBORAH HOHLT | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| MERCK & CO INC | 7 | $16.2M | Q4 2023 | Q3 2024 | yes | |
| NATIONWIDE CHILDREN'S HOSPITAL INC | 7 | $375K | Q4 2023 | Q3 2024 | yes | |
| THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES) | BANNER PUBLIC AFFAIRS, LLC | 7 | $140K | Q4 2023 | Q3 2024 | yes |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | 7 | $13.5M | Q4 2023 | Q3 2024 | yes | |
| THE METROHEALTH SYSTEM | 7 | $940K | Q4 2023 | Q3 2024 | yes | |
| 340B HEALTH | 6 | $1.9M | Q4 2023 | Q3 2024 | yes | |
| HIGHMARK INC | 6 | $1.1M | Q4 2023 | Q3 2024 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 5 | $6.3M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 5 | $20.2M | Q1 2023 | Q1 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 5 | $37.4M | Q4 2023 | Q3 2024 | yes | |
| THE METROHEALTH SYSTEM | ALSTON & BIRD LLP | 5 | $0 | Q4 2023 | Q2 2024 | yes |
| AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 4 | $940K | Q2 2023 | Q3 2024 | yes | |
| AMERIHEALTH CARITAS | GREENBERG TRAURIG, LLP | 4 | $120K | Q1 2023 | Q3 2023 | yes |
| BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) | 4 | $1.0M | Q1 2024 | Q3 2024 | yes | |
| NOVARTIS | 4 | $5.7M | Q1 2023 | Q3 2023 | yes |